Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE Genotype

• DOI: 10.20944/preprints202408.1848.v1
• Publication Date: 2024-08-27T01:09:37Z
• Authors: FIRAT KARA; Kejal Kantarci
• Keywords: Neurochemical; Apolipoprotein E; Postmortem studies; Amyloid (mycology)

In vivo proton (1H) magnetic resonance spectroscopy (MRS) is a powerful noninvasive method which can measure Alzheimer’s disease (AD) related neuropathological alterations at the molecular level. AD biomarkers include amyloid-beta (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles. These be detected via postmortem analysis, but also in living individuals through positron emission tomography (PET) or biofluid of Aβ tau. This review offers an overview biochemical abnormalities by 1H MRS within biologically defined spectrum. It includes summary earlier studies that explored association metabolites with biofluid, PET, biomarkers, examined how apolipoprotein e4 allele carrier status influences brain biochemistry. Studying these associations crucial for understanding pathology affects homeostasis throughout continuum may eventually facilitate to develop potential novel therapeutic approaches.